Complete Guide to Capecitabine and 5-FU Pharmacokinetics
Overview
Capecitabine and 5-FU is a Fluoropyrimidine / Oral Prodrug used in the Oncology therapeutic area. It is indicated for Colorectal cancer, breast cancer, and gastric or gastroesophageal adenocarcinoma. Interactive capecitabine population PK simulator with sequential metabolite modeling from capecitabine to 5'-DFCR, 5'-DFUR, and 5-fluorouracil. Capecitabine is an oral fluoropyrimidine prodrug that is converted to 5-FU, which inhibits thymidylate synthase and disrupts tumor DNA synthesis. Built for colorectal, breast, and gastric cancer PK research and dose exploration.
Mechanism of Action
Capecitabine and 5-FU exerts its pharmacological effect by targeting Thymidylate synthase via intracellular conversion to 5-fluorouracil. As a Fluoropyrimidine / Oral Prodrug, it modulates this target to achieve therapeutic efficacy in Colorectal cancer, breast cancer, and gastric or gastroesophageal adenocarcinoma. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
This Sequential metabolite PopPK (capecitabine to 5'-DFCR to 5'-DFUR to 5-FU) model for Capecitabine and 5-FU characterizes the time-course of drug concentrations following Oral administration. Key parameters such as clearance (CL), volume of distribution (Vd), and absorption rate constant (Ka) define the drug's disposition. Use the interactive simulator below to explore these parameters in detail.
Dosing & Administration
Capecitabine and 5-FU is administered via the Oral route. Oral administration involves absorption from the gastrointestinal tract, and bioavailability may be affected by food intake, formulation, and first-pass metabolism.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology therapeutic area, for the treatment of Colorectal cancer, breast cancer, and gastric or gastroesophageal adenocarcinoma, understanding the pharmacokinetics of Capecitabine and 5-FU is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Capecitabine and 5-FU pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Capecitabine and 5-FU PK Simulator
Explore Capecitabine and 5-FU pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Capecitabine and 5-FU?
The elimination half-life of Capecitabine and 5-FU depends on patient-specific factors. Use our interactive Capecitabine and 5-FU PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Capecitabine and 5-FU administered?
Capecitabine and 5-FU is administered via the Oral route. It is indicated for Colorectal cancer, breast cancer, and gastric or gastroesophageal adenocarcinoma. As a Fluoropyrimidine / Oral Prodrug, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Capecitabine and 5-FU?
Key pharmacokinetic parameters for Capecitabine and 5-FU include clearance (CL), volume of distribution (Vd), and elimination half-life. Our interactive simulator uses a Sequential metabolite PopPK (capecitabine to 5'-DFCR to 5'-DFUR to 5-FU) model to characterize the pharmacokinetics of Capecitabine and 5-FU.
Can I simulate Capecitabine and 5-FU dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Capecitabine and 5-FU PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.